Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPORTANCE: Pembrolizumab with or without radiotherapy in metastatic head and neck squamous cell carcinoma
2017-002122-20Phase 3Terminated
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Primary endpoint: Primary response by iRECIST. Started Jan 2018; status: terminated.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-002122-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002122-20.